Clinical trials: Immunology, active
AIDS
Mesenchymal Stem Cells Treatment for AIDS Patients at Late Stage
The goal of this study is to conduct a prospective, double-blind, randomized placebo-controlled clinical trial to investigate the safety and efficacy of mesenchymal stem cells treatment for AIDS patients at late stage.
- Trial name
- NCT05939167
- Testing
- mesenchymal stem cell, saline
- Where
- 4 sites in China
- Volunteers
- 150 people
- Sponsor
- Cell Energy Life Sciences Group Co. LTD
Glioblastoma, GBM
Surgical Nivolumab And Ipilimumab For Recurrent GBM
This research trial is studying the safety and effectiveness of nivolumab in combination with ipilimumab and surgery when used in the treatment of recurrent glioblastoma.
- Conditions
- Glioblastoma, GBM, Glioblastoma Multiforme, Grade IV Astrocytoma
- Trial name
- NCT04606316
- Testing
- Nivolumab, Ipilimumab, Surgery
- Where
- 3 sites in United States
- Volunteers
- 63 people
- Sponsor
- Gilbert Youssef
HIV (Human Immunodeficiency Virus), Alcohol Misuse
PNF RCT to Decrease Alcohol Use and Increase HIV Prevention
Randomized controlled trial to test the preliminary efficacy and mediating mechanism of a personalized normative feedback intervention on behavioral intentions, heavy alcohol use, and HIV/STI prevention among adolescents and…
- Conditions
- HIV (Human Immunodeficiency Virus), Alcohol Misuse, STI
- Trial name
- NCT07731932
- Testing
- PNF - HIV norms, PNF - Alcohol use norms, PNF - HIV and alcohol use norms
- Where
- Uganda
- Volunteers
- 1,350 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University
HIV Infection
Prevalence of Drug-resistant Hiv-1 Strains in Patients Experiencing Virologic Failure. (MULTIVIR2025)
In this cross-sectional, national and multicenter study, the main objective is to determine the prevalence of multi-drug resistant viruses (i.e., viruses that are resistant or possibly resistant to at least one antiretroviral…
- Trial name
- MULTIVIR2025 (NCT06842706)
- Volunteers
- 800 people
- Sponsor
- ANRS, Emerging Infectious Diseases
NPC Patients, Nasopharyngeal Cancinoma (NPC)
Prospective Immuno-Radiomic Profiling in Nasopharyngeal Carcinoma Treated With Proton or Photon Chemoradiotherapy
To prospectively investigate and integrate radiomic and immunologic signatures in patients with nasopharyngeal carcinoma (NPC) treated with either proton or photon radiotherapy, with the aim of identifying biomarkers associated…
- Trial name
- IMPRINT (NCT07232680)
- Testing
- Proton chemoradiotherapy, Photon chemoradiotherapy
- Where
- Taiwan
- Volunteers
- 500 people
- Sponsor
- Cheng-En Hsieh
GATA2, Immunodeficiency
Allogeneic Hematopoietic Stem Cell Transplantation With Briquilimab-Based Conditioning in Participants With GATA2 Deficiency
Background: People with GATA-binding factor 2 (GATA2) deficiency have a mutation on the GATA2 gene. This gene affects immune function.
- Trial name
- NCT05907746
- Testing
- Mycophenolate Mofetil, Tacrolimus, Post-Transplant Cyclophosphamide
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- National Cancer Institute (NCI)
HIV Infections
Missed Opportunities for HIV Screening in General Practice
The number of new HIV diagnoses in France in 2022 is estimated to be between 4,200 and 5,700. Of these diagnoses, 43% of infections were detected at a late stage.
- Trial name
- DepVIH (NCT07303114)
- Where
- France
- Volunteers
- 50 people
- Sponsor
- University Hospital, Strasbourg, France
Hiv
DOR/TDF/3TC Switch With M184V/I in People With Controlled HIV (Drive Off-Road)
The goal of this pilot, phase 2, single-arm, clinical trial is to assess the antiretroviral combination Doravirine (DOR)/Lamivudine (3TC)/Tenofovir Disproxyl Fumarate (TDF) in participants with suppressed HIV who previously…
- Trial name
- DOR (NCT06034938)
- Testing
- Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate 100 MG-300 MG-300 MG Oral Tablet [DELSTRIGO]
- Where
- 4 sites in France
- Volunteers
- 32 people
- Sponsor
- University Hospital, Caen
HPV Infection
Integration of HPV Vaccination and HPV-based Cervical Screening Into ARV Clinics: the H2VICTORY Trial
A 3-dose HPV vaccination scheme has shown to be safe and immunogenic in people living with HIV (PLWH), although evidence on 1-dose, which is important to improve coverage, is scarce.
- Trial name
- H2VICTORY (NCT05173324)
- Testing
- HPV vaccine, HPV testing, HAV vaccine
- Volunteers
- 8,000 people
- Sponsor
- International Agency for Research on Cancer
HIV Infection
An Adaptive Platform Trial for Evaluation of Novel Treatment Regimens in Children and Adolescents With HIV in Africa
The goal of the CHAPAS-5 clinical trial is to find out how well different HIV treatments work in children and young people (from 4 weeks up to under 15 years old) living with HIV, including those starting treatment for the first…
- Trial name
- CHAPAS-5 (NCT07792096)
- Testing
- Dolutegravir (DTG), Abacavir (ABC), Lamivudine (3TC)
- Volunteers
- 800 people
- Sponsor
- University College, London
AIDS-Related Anal Carcinoma, AIDS-Related Cervical Carcinoma
Screening Algorithms for Cervical and Anal High-Grade Squamous Intraepithelial Lesions in People With HIV in Mexico and Puerto Rico
This clinical trial aims to find what different tests work best to find high-grade squamous intraepithelial lesions (HSIL) in the cervix or anus in patients living with human immunodeficiency virus (HIV).
- Conditions
- AIDS-Related Anal Carcinoma, AIDS-Related Cervical Carcinoma, High Grade Anal Intraepithelial Neoplasia, High Grade Cervical Intraepithelial Neoplasia
- Trial name
- CAMPO-101 (NCT05074264)
- Testing
- Biopsy, Biospecimen Collection - Anal, Biospecimen Collection - Cervical
- Where
- 4 sites in Mexico, Puerto Rico
- Volunteers
- 1,586 people
- Sponsor
- University of California, San Francisco
Metabolic Syndrome, Obesity & Overweight
Effect of Empagliflozin on Metabolic Outcomes in Adults Living With HIV Receiving Dolutegravir-Based Therapy
We investigate the role of empagliflozin in the treatment of obesity in PLWH.
- Conditions
- Metabolic Syndrome, Obesity & Overweight, HIV (Human Immunodeficiency Virus)
- Trial name
- NCT07336797
- Testing
- Empagliflozin (oral)
- Where
- Egypt
- Volunteers
- 66 people
- Sponsor
- Abdelrahman Mahmoud
HIV Infections
A Continued Access Study for Participants Transitioning From ViiV Healthcare-sponsored or ViiV Healthcare-collaborative Parent Studies for HIV Treatment
The purpose of this study is to provide continued access to the study treatment for participants from previous ViiV Healthcare studies who are still benefiting from it and do not have local access after completing the parent…
- Trial name
- PATH (NCT07393659)
- Testing
- Fostemsavir, Dolutegravir (DTG)/ Lamivudine (3TC)
- Where
- 4 sites in South Africa
- Volunteers
- 181 people
- Sponsor
- ViiV Healthcare
Hiv
Pharmacist-led Intervention for Injectable HIV Treatment for Women With Health-related Social Needs
This study addresses real-world use of long-acting injectable cabotegravir/rilpivirine (CAB/RPV LA) by evaluating implementation and clinical outcomes of a pharmacist-led collaborative drug therapy management model (CDTM+) that…
- Trial name
- NCT06411223
- Testing
- Collaborative drug therapy management model, Cabotegravir/Rilpivirine
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Yale University
Opioid Use Disorder, HIV Infections
Buprenorphine Integration Research and Community Health
The goal of this clinical trial is to evaluate an intervention strategy in introducing screen/evaluate/treat (SET) procedures for HIV/ hepatitis C/ and Opioid Use Disorder in Primary Care Clinics in West Virginia.
- Conditions
- Opioid Use Disorder, HIV Infections, Hepatitis C
- Trial name
- BIRCH (NCT05668780)
- Testing
- NIATx Coaching
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Yale University
DOCK8 Deficiency
Pilot Study of Reduced-Intensity Hematopoietic Stem Cell Transplant of DOCK8 Deficiency
Background: -DOCK8 deficiency is a genetic disorder that affects the immune system and can lead to severe recurrent infections and possible death from infections or certain types of cancers, including blood cancers.
- Trial name
- NCT01176006
- Testing
- Reduced-intensity hematopoietic stem cell, Fludarabine(Fludara, Berlex Laboratories), Cyclophosphamide(CTX, Cytoxan)
- Where
- United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
HIV (Human Immunodeficiency Virus)
A Clinical Study Evaluating the Safety, Tolerability, and Effect on HIV Reservoir of Ibalizumab Combined With Chidamide (a Histone Deacetylase Inhibitor) in People Living With HIV
HIV viral reservoirs represent the major barrier to curing AIDS, and effectively reducing viral reservoirs in people living with HIV through different strategies has become a research priority in the HIV field.
- Trial name
- NCT07635992
- Testing
- Ibalizumab Combined with Chidamide
- Volunteers
- 18 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Hepatitis B
Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)
This study will evaluate the efficacy and safety of bepirovirsen compared to placebo in participants with human immunodeficiency virus (HIV)/hepatitis B virus (HBV) co-infection.
- Trial name
- B-Focus (NCT06497504)
- Testing
- Bepirovirsen
- Where
- 51 sites in United States, Argentina and 8 more
- Volunteers
- 153 people
- Sponsor
- GlaxoSmithKline
Hiv, HIV I Infection
Multi Interventional Approaches to Mitigate HIV Reservoirs for the Sustained HIV Remission Without Antiretrovirals
A modern and urgent challenge in fighting HIV infection is to achieve sustained HIV remission without the use of antiretrovirals.
- Trial name
- NCT06805656
- Testing
- Maraviroc, Dolutegravir, Dendritic Cell Vaccine
- Where
- Brazil
- Volunteers
- 70 people
- Sponsor
- Federal University of São Paulo
HIV Infections
A Study to Investigate Safety, Tolerability and Pharmacokinetics of VH5356136 in Adult Participants Without HIV
The study aims to evaluate the safety, tolerability and pharmacokinetic (PK) properties of a single dose of VH5356136 in adult participants without human immunodeficiency virus (HIV).
- Trial name
- NCT07822477
- Testing
- VH5356136 Formulation 1, VH5356136 Formulation 2
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare